High incidence of TERT mutation in brain tumor cell lines

Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

Network TCGA (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061–1068

Brennan CW et al (2013) The somatic genomic landscape of glioblastoma. Cell 155(2):462–477

Parsons DW et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812

Hahn WC et al (1999) Creation of human tumour cells with defined genetic elements. Nature 400(6743):464–468

Martinez P, Blasco MA (2011) Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer 11(3):161–176

Kim NW et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266(5193):2011–2015

Huang FW et al (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122):957–959

Bell RJ et al (2015) Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 348(6238):1036–1039

Killela PJ et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110(15):6021–6026

Heidenreich B et al (2014) TERT promoter mutations in cancer development. Curr Opin Genet Dev 24:30–37

Heidenreich B et al (2015) TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. Oncotarget 6(12):10617–10633

Labussiere M et al (2014) Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology 83(13):1200–1206

Barretina J et al (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603–607

Mao DD et al (2015) A CDC20-APC/SOX2 signaling axis regulates human glioblastoma stem-like cells. Cell Rep 11(11):1809–1821

Eckel-Passow JE et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372(26):2499–2508

Simon M et al (2015) TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol 17(1):45–52

Sahm F et al (2016) TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst 108(5). doi: 10.1093/jnci/djv377

Goutagny S et al (2014) High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol 24(2):184–189

Cancer Genome Atlas Research network et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372(26):2481–2498

Stewart SA et al (2002) Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 99(20):12606–12611

Huang FW et al (2015) TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis 4:e176

Shankar GM et al (2015) Rapid intraoperative molecular characterization of glioma. JAMA Oncol 1(5):662–667

Arita H et al (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126(2):267–276

Greider CW (2012) Molecular biology. Wnt regulates TERT—putting the horse before the cart. Science 336(6088):1519–1520